Are Cardiac Risks of Rosiglitazone Legitimate?

By Kuznar, Wayne | Drug Topics, July 23, 2007 | Go to article overview

Are Cardiac Risks of Rosiglitazone Legitimate?


Kuznar, Wayne, Drug Topics


The controversy surrounding rosiglitazone (Avandia, GlaxoSmithKline) and cardiac risk prompted the addition of a special symposium devoted to this topic at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) held recently in Chicago.

Standing behind a meta-analysis showing excess cardiac risk associated with rosiglitazone was Steven E. Nissen, M.D., lead investigator of the meta-analysis (New England Journal of Mediane 2007;356:2457-2471). The 43% relative excess hazard of myocardial infarction (MI) found with rosiglitazone compared with controls in his analysis of 42 randomized trials, most of them unpublished, is in line with Glaxo's own meta-analysis provided to the Food & Drug Administration in 2006, and with an independent analysis conducted by the FDA, he said.

Subsequently, an observational study performed by Glaxo found no such excess cardiac risk with rosiglitazone, but Nissen pointed out several flaws in this study. It used an insurance claims database with an incomplete assessment of covariates, it followed patients for only one year, and it included no comparison with the other marketed thiazolidinedione, pioglitazone (Actos, Takeda). "In my view, this study was very weak," said Nissen, chairman of cardiovascular medicine at the Cleveland Clinic.

In assessing Nissen's meta-analysis, Philip Home, DM, accused him of "data snooping on quite a big scale." In reaction to the meta-analysis, Home released interim data from a prospective trial designed to address cardiovascular safety with rosiglitazone. The study, known as RECORD (Rosiglitazone Evaluated for Cardiac Outcomes & Regulation of Glycemia in Diabetes), found no increased risk of rosiglitazone on a composite endpoint of hospitalizations and death from cardiovascular causes, compared with metformin and a sulfonylurea, at an unplanned analysis at 3.75 years (N Engl J Med 2007;June 5).

Based on these interim data, rosiglitazone should maintain a role in the glucose-lowering armamentarium, and "RECORD should continue to its planned end," which is a total of five years, said Home, professor of diabetes medicine, University of Newcastle upon Tyne, U.K.

"Major errors in design have rendered this study futile," said Nissen in enumerating the weaknesses of RECORD. The openlabel design and the chosen endpoint, which did not include MI, are two such weaknesses. Another is that the annual event rate in RECORD was only 3. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Are Cardiac Risks of Rosiglitazone Legitimate?
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.